The 17G10.2 monoclonal antibody specifically binds to human Immunoglobulin Like Transcript 7 (ILT7), also known as CD85g. The ILT7 protein is encoded by the LILRA4 (Leukocyte Immunoglobulin Like Receptor subfamily A member 4) gene. ILT7 is a member of immunoglobulin-like transcripts (ILT) or leukocyte immunoglobulin-like receptor (LIR) gene family. ILT7 is selectively expressed on plasmacytoid dendrtic cells (pDC) but not on myeloid dendritic cells or other peripheral blood leukocytes. In response to IL-3, IL-3 receptor complex signaling downregulates ILT7 expression by pDC. ILT7 associates with the FcεRIγ signal adapter protein to form a receptor complex that can signal through activation of an immunoreceptor-based tyrosine activation motif (ITAM)-mediated signaling pathway. Signaling through the ILT7-FcεRIγ receptor complex negatively regulates the innate immune functions of pDC. ILT7 crosslinking inhibits TLR responses by pDC such as the stimulated production of type I interferon and other cytokines. Bone marrow stromal cell antigen 2 (BST2) has been identified as a biological ligand for ILT7.
The antibody was conjugated to BD Horizon™ BB700, which is part of the BD Horizon Brilliant™ Blue family of dyes. It is a polymer-based tandem dye developed exclusively by BD Biosciences. With an excitation max of 485 nm and an emission max of 693 nm, BD Horizon BB700 can be excited by the 488 nm laser and detected in a standard PerCP-Cy™5.5 set (eg, 695/40-nm filter). This dye provides a much brighter alternative to PerCP-Cy5.5 with less cross laser excitation off the 405 nm and 355 nm lasers.